Drug
Vamifeport
Vamifeport: highest development phase Phase 2, developed by CSL. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- CSL
Trials
| Drug | Phase | Indication |
|---|---|---|
| Vamifeport NCT07332091 | Phase 2 | Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis |
Latest
No recent events.
Follow Vamifeport on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.